RARA CRAFT DATABASE for FDA Medical Devices
510(k)K261280

FDA DEVICE FACTS

BioSieve Multi-Drug Urine Test Panel;BioSieve Multi-Drug Urine Home Test Panel

Vivachek Biotech (Hangzhou) Co., Ltd.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEMay 22, 2026PRODUCT CODENFT

Indications for use

BioSieve™ Multi-Drug Urine Test Panel tests are competitive binding, lateral flow immunochromatographic assays for qualitative and simultaneous detection of Amphetamine, Buprenorphine, Secobarbital, Oxazepam, Cocaine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Methadone, Oxycodone, Phencyclidine, Propoxyphene, Nortriptyline, Cannabinoids, Tramadol, Fentanyl, 6-Monoacetylmorphine and Norfentanyl in human urine at the cutoff concentrations of: Drug | Calibrator | Cut-off (ng/mL) Amphetamine (AMP) | D-Amphetamine | 1,000 or 500 Secobarbital (BAR) | Secobarbital | 300 Buprenorphine (BUP) | Buprenorphine | 10 Oxazepam (BZO) | Oxazepam | 300 Cocaine (COC) | Benzoylecgonine | 300 or 150 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) | 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine | 300 Ecstasy (MDMA) | D,L-Methylenedioxy-methamphetamine | 500 Methamphetamine (MET) | D-Methamphetamine | 1,000 or 500 Morphine (MOP/OPI) | Morphine | 2,000 or 300 Methadone (MTD) | Methadone | 300 Oxycodone (OXY) | Oxycodone | 100 Phencyclidine (PCP) | Phencyclidine | 25 Propoxyphene (PPX) | Propoxyphene | 300 Nortriptyline (TCA) | Nortriptyline | 1,000 Marijuana (THC) | 11-nor-Δ9-THC-9 COOH | 50 Tramadol (TRA) | Tramadol | 100 Fentanyl (FYL) | Fentanyl | 1 6-Monoacetylmorphine (6-MAM) | 6-Monoacetylmorphine | 10 Norfentanyl (NFYL) | Norfentanyl | 5 The single or multi-test panel can consist of up to nineteen (19) of the above listed analytes in any combination. It is for in vitro diagnostic use only. The tests may yield positive results for the prescription drugs Buprenorphine, Nortriptyline, Oxazepam, Secobarbital, Propoxyphene, and Oxycodone when taken at or above prescribed doses. It is not intended to distinguish between prescription use or abuse of these drugs. Careful consideration and judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. The tests provide only preliminary results. To obtain a confirmed analytical result, a more specific alternate chemical method must be used. GC/MS or LC/MS is the recommended confirmatory method. BioSieve™ Multi-Drug Urine Home Test Panel is competitive binding, lateral flow immunochromatographic assay for qualitative and simultaneous detection of Amphetamine, Buprenorphine, Secobarbital, Oxazepam, Cocaine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Methadone, Oxycodone, Phencyclidine, Propoxyphene, Nortriptyline, Marijuana, Tramadol, Fentanyl, 6-Monoacetylmorphine and Norfentanyl in human urine at the cutoff concentrations of: Drug (Identifier) | Cut-off level Amphetamine (AMP) | 500 ng/mL or 1000 ng/mL Buprenorphine (BUP) | 10 ng/mL Secobarbital (BAR) | 300 ng/mL Oxazepam (BZO) | 300 ng/mL Cocaine (COC) | 150 ng/mL or 300 ng/mL 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) | 300 ng/mL Methamphetamine (MET) | 500 ng/mL or 1000 ng/mL Methylenedioxymethamphetamine (MDMA) | 500 ng/mL Morphine (MOP 300/OPI 2000) | 300 ng/mL or 2000 ng/mL Methadone (MTD) | 300 ng/mL Oxycodone (OXY) | 100 ng/mL Phencyclidine (PCP) | 25 ng/mL Propoxyphene (PPX) | 300 ng/mL Nortriptyline (TCA) | 1000 ng/mL Marijuana (THC) | 50 ng/mL Tramadol (TRA) | 100 ng/mL Fentanyl (FYL) | 1 ng/mL 6-Monoacetylmorphine (6-MAM) | 10 ng/mL Norfentanyl (NFYL) | 5 ng/mL The single or multi-test panel can consist of up to nineteen (19) of the above listed analytes in any combination. It is for in vitro diagnostic use only. It is intended for OTC use. The test may yield positive results for the prescription drugs Buprenorphine, Oxazepam, Secobarbital, Nortriptyline, Propoxyphene and Oxycodone when taken at or above prescribed doses. It is not intended to distinguish between prescription use or abuse of these drugs. Careful consideration and judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. The tests provide only preliminary results. To obtain a confirmed analytical result, a more specific alternative chemical method must be used. GC/MS or LC/MS is the recommended confirmatory method.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: July 28, 2026